Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab). ctDNA is genetic material from tumor cells that can be found and measured in the blood
Epistemonikos ID: 6e6a875807e29f8e94e64175b8a56c2b69f10a09
First added on: May 15, 2024